Increased MYBL2 expression in aggressive hormone‐sensitive prostate cancer
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13314
Abstract: Loss of the histone demethylase KDM5D (lysine‐specific demethylase 5D) leads to in vitro resistance of prostate cancer cells to androgen deprivation therapy (ADT) with and without docetaxel. We aimed to define downstream drivers of the KDM5D… read more here.
Keywords: prostate cancer; prostate; expression; hormone sensitive ... See more keywords
A Missense Variant Arg611Cys in LIPE which Encodes Hormone Sensitive Lipase Decreases Lipolysis and Increases Risk of Type 2 Diabetes in American Indians.
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes/metabolism research and reviews"
DOI: 10.1002/dmrr.3504
Abstract: AIMS Hormone sensitive lipase (HSL), encoded by the LIPE gene, is involved in lipolysis. Based on prior animal and human studies, LIPE was analyzed as a candidate gene for the development of type 2 diabetes… read more here.
Keywords: cys allele; american indians; hormone sensitive; lipolysis ... See more keywords
Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.
Sign Up to like & getrecommendations! Published in 2019 at "Clinical genitourinary cancer"
DOI: 10.1016/j.clgc.2019.05.001
Abstract: BACKGROUND Results from large randomized controlled trials combining docetaxel, abiraterone, celecoxib, or bisphosphonates with androgen deprivation therapy (ADT) in hormone-sensitive prostate cancer have emerged. However, in our knowledge, few data are available in patients older… read more here.
Keywords: docetaxel abiraterone; hormone sensitive; cancer; addition ... See more keywords
Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis.
Sign Up to like & getrecommendations! Published in 2018 at "European journal of cancer"
DOI: 10.1016/j.ejca.2018.08.010
Abstract: AIM Androgen deprivation therapy (ADT) has long been the gold standard for patients with metastatic hormone-sensitive prostate cancer (mHSPC). Clinical trials have demonstrated significant survival benefits when docetaxel (DOC) or abiraterone acetate (AA) and prednisone… read more here.
Keywords: prostate; hormone sensitive; metastatic hormone; sensitive prostate ... See more keywords
A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer.
Sign Up to like & getrecommendations! Published in 2019 at "European urology oncology"
DOI: 10.1016/j.euo.2019.01.004
Abstract: BACKGROUND Following the recent publication of results from randomized trials that have demonstrated a survival benefit for the addition of docetaxel or abiraterone acetate to androgen deprivation therapy (ADT) in the treatment of metastatic prostate… read more here.
Keywords: adt; treatment; hormone sensitive; metastatic hormone ... See more keywords
Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard.
Sign Up to like & getrecommendations! Published in 2017 at "European urology"
DOI: 10.1016/j.eururo.2017.09.029
Abstract: Addition of docetaxel to androgen deprivation therapy (ADT) was recommended for patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), who are fit enough to receive docetaxel. Two recently published trials showed that the addition… read more here.
Keywords: abiraterone acetate; prostate cancer; hormone sensitive; metastatic hormone ... See more keywords
Identification of a Radiosensitivity Molecular Signature Induced by Enzalutamide in Hormone-sensitive and Hormone-resistant Prostate Cancer Cells
Sign Up to like & getrecommendations! Published in 2019 at "Scientific Reports"
DOI: 10.1038/s41598-019-44991-w
Abstract: Prostate cancer (PCa) is the most common cancer amongst men. A novel androgen receptor (AR) antagonist, enzalutamide (ENZA) has recently been demonstrated to enhance the effect of radiation (XRT) by impairing the DNA damage repair… read more here.
Keywords: hormone; hormone resistant; prostate cancer; hormone sensitive ... See more keywords
How I Treat Metastatic Hormone-Sensitive Prostate Cancer?
Sign Up to like & getrecommendations! Published in 2021 at "Indian Journal of Medical and Paediatric Oncology"
DOI: 10.1055/s-0041-1729725
Abstract: Androgen deprivation therapy (ADT) combined with docetaxel or antiandrogens (abiraterone, enzalutamide, or apalutamide) improved the outcomes in men with metastatic hormone-sensitive prostate cancer (mHSPC). When multiple options are available, the dilemma remains how to choose… read more here.
Keywords: metastatic hormone; sensitive prostate; prostate cancer; hormone sensitive ... See more keywords
mRNA expressions of androgen receptor and its variants in matched hormone-sensitive and castration-resistant prostate cancer
Sign Up to like & getrecommendations! Published in 2019 at "Scandinavian Journal of Urology"
DOI: 10.1080/21681805.2019.1697359
Abstract: Abstract Objectives: Androgen receptor splice variants (AR-Vs), especially androgen receptor splice variant 7 (AR-V7), are considered as important factors in developing castration-resistance of prostate cancer and also as candidate predictive factors. Our aim was to… read more here.
Keywords: prostate; prostate cancer; hormone sensitive; castration ... See more keywords
Efficacy of enzalutamide in hormone-sensitive metastatic prostate cancer: Clinical utility of 18F-choline PET and whole body MRI
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz248.043
Abstract: Abstract Background AR-inhibition with Enzalutamide may be an attractive alternative for 1L treatment of men with hormone-sensitive prostate cancer compared to androgen deprivation therapy (ADT). There is an unmet need for robust, reproducible imaging technology… read more here.
Keywords: hormone sensitive; prostate cancer; 18f choline; choline pet ... See more keywords
Prognostic impact of sarcopenia in patients with metastatic hormone-sensitive prostate cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Japanese journal of clinical oncology"
DOI: 10.1093/jjco/hyaa045
Abstract: BACKGROUND Cancer cachexia is associated with a poor prognosis. This study aimed to investigate the association between sarcopenia and survival in patients with metastatic hormone-sensitive prostate cancer. METHODS We retrospectively evaluated 197 patients diagnosed with… read more here.
Keywords: prostate cancer; hormone sensitive; metastatic hormone; sensitive prostate ... See more keywords